14 completed, 4 terminated, 3 withdrawn, 2 active not recruiting. 21 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 12, Terminated 4, Withdrawn 3, Active not recruiting 2 |
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Mereo BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta Setrusumab - Osteogenesis Imperfecta | Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 2 | 2022-04-28 | 2025-07-23 |
| Setrusumab vs Placebo for Osteogenesis Imperfecta Setrusumab, Placebo - Osteogenesis Imperfecta | Phase 2 / Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 183 | 2022-02-21 | 2026-10-20 |
| EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Nivolumab, Etigilimab - Ovarian Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2021-10-01 | 2026-09-25 |
| MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation MPH966, Placebo - Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Nelson Chao | 2021-09-01 | 2020-03-20 | |
| A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors Etigilimab, Nivolumab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Mereo BioPharma | 76 | 2021-03-23 | 2025-03-17 |
| COVID-19 Study of Safety and Tolerability of Alvelestat Alvelestat, Placebo - Covid19 | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 15 | 2021-01-25 | 2023-01-19 |
| Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency Alvelestat (MPH966), Placebo - Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations | Phase 2 | Completed | University of Alabama at Birmingham | 63 | 2019-04-08 | 2024-08-20 |
| A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2 - Alpha 1-Antitrypsin Deficiency, Emphysema | Phase 2 | Completed | Mereo BioPharma | 99 | 2018-10-29 | 2022-04-14 |
| The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants BCT197, Itraconazole 200 mg - Interaction | Phase 1 | Completed | Mereo BioPharma | 16 | 2018-03-19 | 2018-05-18 |
| An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta BPS804 - Osteogenesis Imperfecta | Phase 2 | Withdrawn | Ultragenyx Pharmaceutical Inc | 2017-10-31 | 2023-07-03 | |
| A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 setrusumab, Calcium, Vitamin D - Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 112 | 2017-09-11 | 2023-07-05 |
| A 6 Month Safety Extension Study of MBGS205 BGS649 - Hypogonadotropic Hypogonadism | Phase 2 | Completed | Mereo BioPharma | 143 | 2016-11-15 | 2023-05-18 |
| The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers BCT197, Azithromycin - Interaction | Phase 1 | Completed | Mereo BioPharma | 16 | 2016-09-01 | 2016-10-24 |
| Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease BCT197, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Mereo BioPharma | 282 | 2016-08-01 | 2020-11-30 |
| Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism BGS649, Placebo - Hypogonadotropic Hypogonadism | Phase 2 | Completed | Mereo BioPharma | 271 | 2016-05-12 | 2022-09-14 |
| Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease BPS804, Placebo - Chronic-kidney Disease Stage 5D on Stable Hemodialysis | Phase 2 | Withdrawn | Ultragenyx Pharmaceutical Inc | 2013-08-01 | 2022-09-14 | |
| Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery BCT197 Part A, Placebo, BCT197 Part B - Acute Kidney Injury | Phase 2 | Terminated | Mereo BioPharma | 91 | 2011-09-01 | 2020-11-06 |
| Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) BPS804 - Hypophosphatasia | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 8 | 2011-07-01 | 2022-09-16 |
| Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804 - Osteopenia, Osteoporosis | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 44 | 2011-07-01 | 2022-09-15 |
| Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation BCT197, Prednisone placebo, BCT197 placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Mereo BioPharma | 183 | 2011-03-01 | 2023-03-21 |
Showing 20 of 23. Sign in to see all of them.
Osteogenesis Imperfecta (4) · Pulmonary Disease, Chronic Obstructive (4) · Hypogonadism (3) · Emphysema (2) · Endometriosis (2) · alpha 1-Antitrypsin Deficiency (2) · Acute Kidney Injury (1) · Bone Diseases, Metabolic (1) · COVID-19 (1) · Dysmenorrhea (1) · Hematologic Neoplasms (1) · Hypophosphatasia (1) · Infertility (1) · Lung Diseases (1) · Neoplasm Metastasis (1)
setrusumab (7) · Nivolumab (2) · acumapimod (2) · Azithromycin (1) · Calcium (1) · Itraconazole (1) · Prednisone (1) · Vitamin D (1) · Zoledronic Acid (1) · leflutrozole (1)
United States (19) · United Kingdom (6) · Canada (4) · Germany (3) · Italy (3) · Poland (3) · Bulgaria (2) · Denmark (2) · France (2) · Romania (2) · Russia (2) · Spain (2) · Australia (1) · Belgium (1) · Czechia (1)
Jacqueline Parkin, PhD FRCP (8) · Hugh Jones (2) · Anthony Sung, MD (1) · James M Wells, MD (1) · Mark T Dransfield, MD (1) · Robert Stockley, Prof. (1) · Shannon Westin, MD (1)
PMID 28436937, PMID 31682162, PMID 37579053, PMID 39012717, PMID 42470570
2016 (1), 2018 (1), 4UH3TR002450-02 (1)